加拿大上皮样血管内皮瘤(EHE)患者发病率、患病率及治疗:CanSaRCC与PRO_CARE EHE研究
中位无事件生存期(EFS)为5.5年(95%CI 3.4-8.5),中位总生存期(OS)为8.6年(95%CI 5.4-16.5);多因素分析显示高龄、胸腔积液、腹水、原发肺疾病及转移性疾病与不良生存相关。
要点
- EHE为超罕见肉瘤,常伴WWTR1-CAMTA1或YAP1-TFE3基因融合。
- 本队列45.7%初诊即转移,31%为 incidental 发现,肝、四肢、肺为常见原发部位。
- 仅27.8%患者接受过至少一线全身治疗,常用药物包括西罗莫司、帕唑帕尼和紫杉醇。
核心结论
- 这是描述EHE患者序贯全身治疗的最大系列研究,但全身治疗对生存改善的作用仍不明确,需前瞻性对照研究进一步阐明。
主要发现
- 198例患者中94例(45.7%)初诊时即有转移,61例(31%)为偶然诊断。
- 最常见原发部位为肝脏(n=56,28.3%)、四肢(n=31,15.7%)和肺(n=27,13.6%)。
- 43例(22%)患者进行了融合基因检测且结果阳性。
- 55例(27.8%)患者接受至少一线全身治疗,最常用药物包括西罗莫司、帕唑帕尼和紫杉醇。
- 中位无事件生存期(EFS)为5.5年(95%CI 3.4-8.5),中位总生存期(OS)为8.6年(95%CI 5.4-16.5)。
关键数值与推荐
- 7例患者接受了肝移植。
临床怎么用
- EHE临床表现异质,初诊时需评估转移情况,肝、四肢、肺原发者应纳入重点监测。
- 全身治疗选择包括西罗莫司、帕唑帕尼和紫杉醇,但生存获益尚不明确,需个体化决策。
- 高龄、胸腔积液、腹水、原发肺疾病及转移性疾病提示预后不良,可加强随访。
局限性
- 回顾性数据库研究,全身治疗对生存的作用无法得出因果结论,需前瞻性对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Epithelioid Haemangioendothelioma (EHE) is an ultra-rare sarcoma characterized by WWTR1-CAMTA1 or YAP1-TFE3 gene fusions. Clinical behaviour ranges from indolent to aggressive. Due to its rarity, this study aims to describe the presentation, management, and outcomes of EHE patients in Canada. METHODS: Data was collected and entered to the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) database. Patients of all ages with a documented diagnosis of EHE from Nov 1993 to Jan 2024 were included. Patient demographics, disease characteristics and treatment details were collected using a case report form and summarized using descriptive statistics. Kaplan-Meier method was used to estimate overall survival and event free survival. Cox regression was used to estimate factors influencing survival outcomes. RESULTS: In total, 198 patients were included of which 94 (45.7 %) presented with metastatic disease. The diagnosis was incidental in 61 patients (31 %). The most frequent primary sites were liver (n = 56, 28.3 %), extremities (n = 31, 15.7 %) and lungs (n = 27, 13.6 %). Fusion testing was performed and positive in 43 (22 %) patients. At least one line of systemic therapy was used in 55 (27.8 %) patients with most common agents including sirolimus, pazopanib and paclitaxel. The median EFS was 5.5 years (95 % CI: 3.4-8.5), and the median OS was 8.6 years (95 % CI: 5.4 - 16.5). Liver transplant was performed in seven patients. In multivariate analysis, older age, pleural effusion, ascites, primary lung disease and metastatic disease were associated with poor survival outcomes. CONCLUSION: This is the largest series of EHE patients describing sequential systemic therapies. The role of systemic therapy in EHE in improving survival remains unclear and prospective studies with comparative arms are needed to add further insight into this chronic disease.
引用
- Weadick CS, Alshibany A, Michael MJ, et al. Incidence, prevalence and treatment of patients with Epithelioid Haemangioendothelioma (EHE) in Canada: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) and Multi-pronged Canadian Research in Epithelioid Haemangioendothelioma (PRO_CARE EHE) study. Eur J Cancer. 2025. PMID: 41218239. doi:10.1016/j.ejca.2025.116100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。